Sanofi is in the final stages of selling its European generics business, Zentiva, to private equity firm Advent International. The companies have signed a share purchase agreement valued at €1.9 ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

Creditors are ready to provide debt financing in the amount of 3 billion euros as part of the proposed acquisition of the manufacturer of Zentiva generics. This is reported by foreign media. Earlier, ...

Background: The relative superiority of atezolizumab–bevacizumab versus pembrolizumab-lenvatinib in treatment of unresectable hepatocellular carcinoma (HCC) remains uncertain. This study aims to ...